CAS
AQST icon

Coppell Advisory Solutions’s Aquestive Therapeutics AQST Stock Holding History

Coppell Advisory Solutions’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-16
Closed -$76 – 1979
2024
Q3 		$76 Hold
16
– – ﹤0.01% 1811
2024
Q2 		$42 Buy
+16
New +$53 ﹤0.01% 1760
2023
Q4 		$32 Sell
16
-21
-57% -$37 ﹤0.01% 1689
2023
Q3 		$33 Buy
37
+21
+131% +$36 ﹤0.01% 1179
2023
Q2 		$25 Buy
+16
New +$29 ﹤0.01% 1416
2023
Q1 		– Sell
-37
Closed -$33 – 251
2022
Q4 		$33 Buy
+37
New +$35 ﹤0.01% 1180

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Coppell Advisory Solutions's AQST Position: Q4 2024 in Review

Coppell Advisory Solutions sold out of Aquestive Therapeutics (AQST) in Q4 2024, closing a stake of 16 shares — an estimated $76 sold.

Coppell Advisory Solutions first reported a position in AQST in Q4 2022 and held it in 6 quarters. The position peaked at $76 in Q3 2024. 114 funds tracked by Wall St. Rank hold AQST as of Q4 2024.

  • Coppell Advisory Solutions reported no remaining Aquestive Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Coppell Advisory Solutions sold 16 Aquestive Therapeutics shares in Q4 2024, an estimated $76.
  • Coppell Advisory Solutions first reported a position in Aquestive Therapeutics in Q4 2022 and held it in 6 quarters.
  • Coppell Advisory Solutions's Aquestive Therapeutics position peaked at $76 in Q3 2024.
  • 114 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2024.

Based on Coppell Advisory Solutions's 13F filing for Q4 2024, filed 14 Feb 2025.